# Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT

> **NCT04516551** · PHASE1 · UNKNOWN · sponsor: **Xinqiao Hospital of Chongqing** · enrollment: 18 (estimated)

## Conditions studied

- Relapsed Adult ALL
- B Cell Leukemia

## Interventions

- **BIOLOGICAL:** anti-CD19 allo-CAR-T cells

## Key facts

- **NCT ID:** NCT04516551
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-20
- **Primary completion:** 2021-12-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2020-11-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04516551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04516551, "Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04516551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*